The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| Clovis Oncology, Inc. | Common Stock | 189464100 | 14,687,347 | 407,416 | SH | OTR | 0 | 407,416 | 0 | ||
| CymaBay Therapeutics, Inc. | Common Stock | 23257D103 | 2,034,286 | 1,048,601 | SH | OTR | 0 | 1,048,601 | 0 | ||
| Achaogen, Inc. | Common Stock | 004449104 | 6,136,718 | 1,281,152 | SH | OTR | 0 | 1,281,152 | 0 | ||
| Ocular Therapeutix, Inc. | Common Stock | 67576A100 | 15,219,688 | 2,215,384 | SH | OTR | 0 | 2,215,384 | 0 | ||
| Glaukos Corporation | Common Stock | 377322102 | 2,695,693 | 71,428 | SH | OTR | 0 | 71,428 | 0 | ||
| Audentes Therapeutics, Inc. | Common Stock | 05070R104 | 32,179,678 | 1,806,832 | SH | OTR | 0 | 1,806,832 | 0 | ||
| Immune Design Corp. | Common Stock | 45252L103 | 16,738,232 | 2,208,210 | SH | OTR | 0 | 2,208,210 | 0 | ||